RECENT NOTABLE ACTIVITY – MEDICAL DEVICES
- NeoTract, a developer of minimally invasive devices to treat lower urinary tract symptoms, is to be acquired by Teleflex for $1.1B. Link
- Vertera Spine, a developer of interbody implants for spinal fusion, is to be acquired by NuVasive. Link
- Minimally Invasive Devices, a developer of Laparoscopic visualization system, is to be acquired by McAfee Capital. Link
- ClearCorrect, a developer of of clear alignersof clear aligners, is to be acquired by Straumann Group. Link
- Medi-Line, a developer of active and non-active implants, is to be acquired by Nexeon MedSystems. Link
- BioQ Pharma, a developer of ready‐to‐use infusible pharmaceuticals for post-surgical pain and sedation, raised $55M in a Series D round led by Madryn Asset Management. Link
- Establishment Labs, a developer of silicone-filled breast and body shaping implants, raised $55M in a Series D round, led by Madryn Asset Management. Link
- ElectroCore, a developer of non-invasive vagus nerve stimulation devices, raised $36M in a Series B round. Link
- SetPoint Medical, a developer of bioelectronic therapy for chronic inflammatory diseases, raised $30M in a Series D round. Link
- ClaroNav received FDA 510(k) clearance for its NaviENT surgical navigation system designed for endoscopic sinus surgery and skull base surgery. Link
- NuVasive received FDA 510(k) clearance for its redesigned Magec magnetically controlled growth modulation system. Link
- Adherium received FDA 510(k) clearance for its smart inhaler monitoring device. Link
- Smiths Medical received FDA 510(k) clearance for its CADD-Solis wireless ambulatory infusion pump. Link
- Camber Spine Technologies received FDA 510(k) clearance for its Spira open matrix anterior lumbar interbody fusion device. Link
SOME INTERESTING STARTUPS FOUND
Attune Medical (Unfunded, Chicago, 2017) – An Esophageal cooling device.
IanTech (Undisclosed, Reno, 2015) – An interventional device for cataract surgery.
LEADER BOARD – MEDICAL DEVICES
Cardiovascular
TriVascular (1998, Santa Rosa, IPO) – Medical devices for endovascular aortic repair. Backed by NEA, Pinnacle Ventures, Greenspring Associates, Kaiser Permanente Ventures, ABS Ventures, MPM Capital, Delphi Ventures, Kearny Venture Partners, De Novo Ventures, Deerfield Capital Management, Helix Ventures, Deerfield, Permal, Pinnacle Ventures, and Rock Springs Capital. Went public in 2014.
Cardiovascular Systems (1989, Saint Paul, IPO) – Devices treating peripheral and coronary vascular disease. Backed by Silicon Valley Bank, Mitsui Global Investment, TPG, Healthcare Ventures, Lumira Capital, and Partners for Growth. Went public in 2006.
Orthopedics
ConforMIS (2004, Bedford, IPO) – Personalized, partial knee resurfacing implants to treat knee osteoarthritis. Backed by Aeris Capital, and Centurion. Went public in 2015.
Amedica (1996, Salt Lake City, IPO) – Spinal implants based on silicon nitride ceramic technology platform. Backed by Morningside Ventures, Zions Bank, Oxford Finance, venBio Partners, Hillhouse Capital, Epidarex Capital, and AJU IB Investment U.S. Went public in 2014.
Ophthalmology
Glaukos (2001, Laguna Hills, IPO) – Developed Micro-Invasive Glaucoma Surgery implant to treat glaucoma. Backed by Orbimed, Meritech Capital, InterWest Partners, Frazier Healthcare Partners, Versant Ventures, Novo A/S, Domain Associates, Fjord Ventures, and Montreux Equity Partners. Went public in 2015.
Ocular Therapeutix (2006, Bedford, IPO) – Develops Ophthalmic therapeutic products by using hydrogel technology. Backed by Polaris Partners, Ascension Ventures, Versant Ventures, SV Life Sciences, Baxter, Pinnacle Ventures, and Ascension Ventures. Went public in 2014.
Diabetes Mellitus
Senseonics (1996, Germantown, IPO) – Implantable system for continuous glucose monitoring. Backed by NEA, Rho Capital Partners, Greenspring Associates, Rho Ventures, Anthem Capital Management, Abingworth, Delphi Ventures, Healthcare Ventures, and Anthem Capital. Went public in 2016.
Tandem Diabetes (2008, San Diego, IPO) – Device for continuous glucose monitoring and manual insulin delivery. Backed by TPG, HLM Venture Partners, Domain Associates, Delphi Ventures, and Kearny Venture Partners. Went public in 2013.
Oncology
ViewRay (2004, Oakwood, IPO) – MRI-guided radiation therapy technology for cancer. Backed by Fidelity Investments, Orbimed, Siemens, ITOCHU Technology Ventures, Fidelity Growth Partners Europe, HTGC, Fidelity Biosciences, Kearny Venture Partners, Aisling Capital, Montrose Capital Partners, Xeraya Capital, CRG, and F-Prime Capital Partners. Went public in 2015.
GeneNews (1998, Markham, IPO) – Blood-based molecular diagnostics. Went public in 2001.
Neurology
Nexstim (2000, Helsinki, IPO) – Noninvasive brain stimulation for rehabilitating stroke patients. Backed by Capricorn Venture Partners, Suomen Teollisuussijoitus, Life Sciences Partners, Lundbeckfond Ventures, Healthcap, Finnish Industry Investment, Lundbeckfonden, and Healthcap. Went public in 2014.
Vycor Medical (2005, Boca Raton, IPO) – Minimally-invasive surgical devices & therapies for neurological disease. Went public in 2009.
Women’s Health
Bovie Medical (1970, Clearwater, IPO) – Manufactures electrosurgical products for gynecologic applications. Backed by Great Point Partners. Went public in 2000.
Viveve Medical (2005, Sunnyvale, IPO) – RF therapy for vaginal laxity. Bridge Bank, 5AM Ventures, GBS Venture Partners, Wexford Capital, Square 1 Bank, RTW Investments, and Stone Pine Capital LLC. Went public in 2016.
Pulmonology
Inogen (2001, Goleta, IPO) – Portable Oxygen Concentrator for Oxygen Therapy. Backed by Western Technology Investment, Avalon Ventures, Versant Ventures, Novo A/S, Arboretum Ventures, and Accuitive Medical Ventures. We
Aerogen (2000, Galway, IPO) – Develops Aerosol drug delivery devices. Backed by J.P. Morgan, US Venture Partners, InterWest Partners, Western Technology Investment, Invesco, Wheatley Partners, Viridian Investment Partners, Western Development Commission, and Healthcap. Went public in 2000.
Gastroenterology
EndoChoice (2008, Alpharetta, IPO) – Device for gastrointestinal conditions. Backed by Sequoia Capital, Silicon Valley Bank, Accelmed, Council Capital, MidCap Financial, Deerfield, River Cities Capital Funds, Agate Medical investments, Rock Springs Capital, and Envest Private Equity. Went public in 2015.
Mauna Kea Tech (2000, Paris, IPO) – Endomicroscopy devices for Gastrointestinal and Respiratory tracts. Backed by Seventure Partners, Psilos, and Finadvance. Went public in 2011.
Dental & Maxillofacial
Align Technology (1997, San Jose, IPO) – Develops Invisalign clear aligners and other dental products. Backed by KPCB, Questmark Partners, ABS Ventures, Oak Hill Capital Partners, The Carlyle Group, and Tekla Capital Management. Went public in 2001.
Biolase (1987, Irvine, IPO) – Develops Dental lasers and scanning devices. Backed by Oracle Investment Management. Went public in 2003.
ENT
Entellus Medical (2006, Plymouth, IPO) – Suite of products for treating chronic sinusitis. Backed by Greenspring Associates, Split Rock Partners, Essex Woodlands, SV Life Sciences, Covidien and Oxford Finance. Went public in 2015.
Intersect ENT (2003, Menlo Park, IPO) – Develops drug-releasing implant for sinusitis. Backed by Norwest Venture Partners, KPCB, and US Venture Partners. Went public in 2014.
Leaderboard includes all the top funded, IPO and successfully running bootstrapped companies along with their location, founding year and funding amount.
For latest updates, visit the Medical Devices feed.